Medical Communications

60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study

July 22, 2024 Medical Communications 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials

60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites …

News

GSK’s application for Blenrep for MM treatment accepted for EMA review

July 19, 2024 Medical Communications Blenrep, EMA, GSK, Oncology

GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …

News

FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review

July 18, 2024 Medical Communications Atara Biotherapeutics, FDA, Virology, priority review

Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License …

News

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application

July 18, 2024 Medical Communications China, Everest Medicines, NMPA, Nephrology

Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …

News

NICE recommends digital tech for ADHD diagnosis in children and young people

July 16, 2024 Medical Communications ADHD, Diagnostics, NICE

The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …

News

Biophytis gains IND approval from FDA for obesity study

July 11, 2024 Medical Communications Biophytis, IND, Obesity, clinical trial, obesity

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …

News

Roche gains CE Mark for AI glucose monitoring system for diabetes management

July 9, 2024 Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.

News

AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

July 8, 2024 Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …

News

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

July 3, 2024 Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …

News

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024 Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024 Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …

News